Viela Bio


Investor Home

Investor Relations

Company Profile

Viela is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. We believe that our approach – which targets the underlying molecular pathogenesis of the disease – enables us to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple indications for each of our product candidates. Learn more about our clinical pipeline.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Quote

  • Price

  • Change


  • High

Shareholder Tools